News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
608,651 Results
Type
Article (40026)
Company Profile (157)
Press Release (568468)
Multimedia
Podcasts (131)
Webinars (11)
Section
Business (177666)
Career Advice (2007)
Deals (30929)
Drug Delivery (118)
Drug Development (74633)
Employer Resources (154)
FDA (13253)
Job Trends (13434)
News (302356)
Policy (28382)
Tag
Academia (2297)
Accelerated approval (6)
Adcomms (20)
Allergies (77)
Alliances (41373)
ALS (102)
Alzheimer's disease (1379)
Antibody-drug conjugate (ADC) (141)
Approvals (13249)
Artificial intelligence (242)
Autoimmune disease (25)
Automation (12)
Bankruptcy (297)
Best Places to Work (10567)
BIOSECURE Act (21)
Biosimilars (115)
Biotechnology (78)
Bladder cancer (76)
Brain cancer (26)
Breast cancer (255)
Cancer (2111)
Cardiovascular disease (189)
Career advice (1669)
Career pathing (29)
CAR-T (133)
Cell therapy (384)
Cervical cancer (16)
Clinical research (61048)
Collaboration (745)
Company closure (1)
Compensation (364)
Complete response letters (26)
COVID-19 (2220)
CRISPR (39)
C-suite (263)
Cystic fibrosis (96)
Data (2154)
Decentralized trials (2)
Denatured (46)
Depression (48)
Diabetes (272)
Diagnostics (5325)
Digital health (12)
Diversity (9)
Diversity, equity & inclusion (43)
Drug discovery (117)
Drug pricing (126)
Drug shortages (32)
Duchenne muscular dystrophy (101)
Earnings (74491)
Editorial (43)
Employer branding (21)
Employer resources (136)
Events (103304)
Executive appointments (756)
FDA (14442)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (3)
Frontotemporal dementia (9)
Funding (649)
Gene editing (98)
Generative AI (23)
Gene therapy (304)
GLP-1 (766)
Government (3925)
Grass and pollen (4)
Guidances (143)
Healthcare (16790)
Huntington's disease (20)
IgA nephropathy (30)
Immunology and inflammation (130)
Indications (26)
Infectious disease (2359)
Inflammatory bowel disease (138)
Inflation Reduction Act (11)
Influenza (50)
Intellectual property (89)
Interviews (320)
IPO (14032)
IRA (51)
Job creations (3262)
Job search strategy (1442)
Kidney cancer (11)
Labor market (35)
Layoffs (427)
Leadership (20)
Legal (6617)
Liver cancer (60)
Lung cancer (296)
Lymphoma (136)
Machine learning (9)
Management (54)
Manufacturing (307)
MASH (79)
Medical device (10483)
Medtech (10487)
Mergers & acquisitions (17427)
Metabolic disorders (740)
Multiple sclerosis (71)
NASH (22)
Neurodegenerative disease (98)
Neuropsychiatric disorders (32)
Neuroscience (1911)
NextGen: Class of 2025 (5773)
Non-profit (4105)
Now hiring (35)
Obesity (399)
Opinion (248)
Ovarian cancer (80)
Pain (101)
Pancreatic cancer (75)
Parkinson's disease (134)
Partnered (16)
Patents (230)
Patient recruitment (103)
Peanut (41)
People (53284)
Pharmaceutical (80)
Pharmacy benefit managers (22)
Phase I (19000)
Phase II (26550)
Phase III (20492)
Pipeline (1300)
Policy (170)
Postmarket research (2402)
Preclinical (7765)
Press Release (51)
Prostate cancer (103)
Psychedelics (34)
Radiopharmaceuticals (236)
Rare diseases (376)
Real estate (4928)
Recruiting (57)
Regulatory (19855)
Reports (34)
Research institute (2029)
Resumes & cover letters (302)
Rett syndrome (5)
RNA editing (3)
RSV (42)
Schizophrenia (79)
Series A (117)
Series B (72)
Service/supplier (10)
Sickle cell disease (55)
Special edition (20)
Spinal muscular atrophy (137)
Sponsored (25)
Startups (3040)
State (2)
Stomach cancer (13)
Supply chain (66)
Tariffs (54)
The Weekly (83)
Vaccines (588)
Venture capitalists (39)
Weight loss (288)
Women's health (38)
Worklife (19)
Date
Last 7 days (882)
Last 30 days (2745)
Last 365 days (29515)
2025 (10783)
2024 (32149)
2023 (36231)
2022 (46834)
2021 (50329)
2020 (48141)
2019 (41605)
2018 (31548)
2017 (28975)
2016 (28493)
2015 (33137)
2014 (26051)
2013 (21602)
2012 (23553)
2011 (24233)
2010 (22242)
Location
Africa (716)
Alabama (48)
Alaska (5)
Arizona (159)
Arkansas (14)
Asia (37214)
Australia (5603)
California (5435)
Canada (1850)
China (488)
Colorado (245)
Connecticut (238)
Delaware (149)
Europe (81882)
Florida (838)
Georgia (192)
Idaho (44)
Illinois (489)
India (23)
Indiana (305)
Iowa (7)
Japan (165)
Kansas (89)
Kentucky (21)
Louisiana (11)
Maine (64)
Maryland (794)
Massachusetts (4257)
Michigan (181)
Minnesota (338)
Mississippi (2)
Missouri (65)
Montana (26)
Nebraska (23)
Nevada (61)
New Hampshire (51)
New Jersey (1717)
New Mexico (29)
New York (1634)
North Carolina (973)
North Dakota (6)
Northern California (2366)
Ohio (175)
Oklahoma (11)
Oregon (30)
Pennsylvania (1214)
Puerto Rico (14)
Rhode Island (27)
South America (1126)
South Carolina (23)
South Dakota (1)
Southern California (2122)
Tennessee (91)
Texas (820)
United States (21124)
Utah (153)
Virginia (148)
Washington D.C. (63)
Washington State (485)
West Virginia (3)
Wisconsin (48)
608,651 Results for "am pharma holding bv".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
NORDIC GROUP B.V. THROUGH ITS SUBSIDIARY NORDIC PHARMA, INC. (U.S.), PRESENTING PATIENT DATA AND PATIENT EXPERIENCE STUDY FOR LACRIFILL® CANALICULAR GEL, A NOVEL THERAPY FOR DRY EYE, AT THE AMERICAN SOCIETY OF CATARACT AND REFRACTIVE SURGERY ANNUAL MEETING
April 24, 2025
·
4 min read
Press Releases
NORDIC GROUP B.V. THROUGH ITS SUBSIDIARY NORDIC PHARMA, INC. (U.S.), ANNOUNCES LAUNCH OF AUTHORIZED GENERIC OF Maxitrol® (Neomycin and Polymyxin B Sulfates and Dexamethasone Ophthalmic Suspension)
April 25, 2025
·
3 min read
Press Releases
Lantern Pharma to Report First Quarter 2025 Operating & Financial Results on May 15th, 2025 at 9:00 a.m. ET
May 8, 2025
·
5 min read
Press Releases
Zealand Pharma conference call on May 8 at 2pm CET (8am ET) to present first quarter 2025 financial results
May 1, 2025
·
2 min read
Pharm Country
Amring Pharmaceuticals Inc. Announces Name Change to Nordic Pharma, Inc. Under New Nordic Group, B.V. Ownership
Amring Pharmaceuticals Inc. (“Amring”) announces its name change to Nordic Pharma, Inc. on March 4, 2024, following the change in ownership of the company from SEVER Life Sciences, B.V. to Nordic Group, B.V., a subsidiary of SEVER Life Sciences B.V., which occurred on June 1, 2023.
March 4, 2024
·
3 min read
Press Releases
Bulletin from the Annual General Meeting of Vicore Pharma Holding AB (publ)
May 7, 2025
·
4 min read
Press Releases
MilliporeSigma Acquires HUB Organoids Holding B.V., Expands Next-Gen Biology Portfolio
January 7, 2025
·
3 min read
Press Releases
MilliporeSigma to Acquire HUB Organoids Holding B.V., Advancing Next Generation Biology Portfolio
December 17, 2024
·
5 min read
Press Releases
Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 22, 2025
April 16, 2025
·
5 min read
Pharm Country
Nordic Group B.V. Through Its Subsidiary Nordic Pharma, Inc. (U.S.), to Present Data on LACRIFILL® Canalicular Gel, a Novel Therapy for Dry Eye, at the American Society of Cataract and Refractive Surgery Annual Meeting
Nordic Pharma, Inc., a subsidiary of Nordic Group B.V., will be presenting data on LACRIFILL® Canalicular Gel, a novel therapy for dry eye symptoms, during the American Society of Cataract and Refractive Surgery Annual Meeting in Boston, MA on April 5-8, 2024.
April 2, 2024
·
4 min read
1 of 60,866
Next
